Invivyd Q4 2024 PEMGARDA revenue $13.8M (+48% QoQ); FY2024 net loss $169.9M; FDA rejects EUA expansion for treatment

Invivyd, Inc.

Q4 2024 net product revenue $13.8M, up 48% from Q3 $9.3M; full-year 2024 net product revenue $25.4M.
Cash and cash equivalents $69.3M at Dec 31, 2024; targeting near-term profitability by end of 1H 2025 with existing cash and expected revenue growth.
FDA declined request to expand PEMGARDA EUA for treatment of mild-to-moderate COVID-19 in immunocompromised; Invivyd submitted reconsideration request.
Phase 1 data for VYD2311 shows average 17-fold greater neutralization potency than pemivibart; commercial mfg substantially completed.
Net loss for 2024 $169.9M ($1.43 per share) vs $198.6M ($1.81 per share) in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.